Phase 2a Trial
J&J Halts Phase 2a Rheumatoid Arthritis Program for Imaavy (Nipocalimab) after Lackluster Results
Johnson & Johnson; Imaavy; nipocalimab; rheumatoid arthritis; Phase 2a trial; DAISY study; clinical trial failure; anti-TNFα therapy; autoimmune diseases
Immuneering’s Pancreatic Cancer Therapy Shows Promising Results in Phase 2a Trial, Stock Surges 55%
Immuneering, IMM-1-104, Pancreatic Cancer, Phase 2a Trial, MEK Inhibitor, Cancer Therapy, Clinical Trial Results, Stock Surge